A dog model using an implanted system for protracted hepatic arterial chemotherapy

A model for hepatic arterial chemotherapy studies using large dogs and an implantable infusion pump has been developed. Using this technique near complete perfusion (>90%) of the liver can be achieved in vivo as determined by hepatic arterial perfusion scintigraphy with technitium 99m macroaggregated albumin. The system is reliable and has been in use for a total of 1353 days (mean of 104 days, range 52-239) in 13 dogs. Pump implantation causes no apparent acute liver damage based on pre- and post-operative alkaline phosphatase and serum glutamic-pyruvic transaminase determinations and does not affect the general mobility or behavior of the animals. Careful placement of the catheter and attention to the physicochemical properties of the solutions loaded are factors contributing to the success of the model. The model permits comprehensive preclinical pharmacokinetic and toxicologic studies of new or preexistent chemotherapeutic agents in the same device that will be used for later administration in human subjects. By providing the means to examine and develop new treatment modalities, it enables the design of even more potent cytotoxic therapy directed into the tumor vascular bed.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/25999/1/0000065.pd

Overlooking Subvisible Particles in Therapeutic Protein Products: Gaps That May Compromise Product Quality

Therapeutic protein products provide unique and effective treatments for numerous human diseases and medical conditions. In many cases, these treatments are used chronically to slow disease progression, reduce morbidity and/or to replace essential proteins that are not produced endogenously in patients. Therefore, any factor that reduces or eliminates the effectiveness of the treatment can lead to patient suffering and even death. One means by which efficacy of therapeutic proteins can be compromised is by an immune response, resulting in antibody-mediated neutralization of the protein’s activity or alterations in bioavailability.1,2 For example, in the case of treatment of hemophilia A, neutralizing antibodies to Factor VIII can cause life-threatening bleeding episodes, resulting in significant morbidity and necessitating treatment with a prolonged course of a tolerance-inducing therapy to reverse immunity.3,4 In other cases, drug-induced antibodies to a therapeutic version of an endogenous protein can cross-react with and neutralize the patient’s endogenous protein. If the endogenous protein serves a non-redundant biological function, such an immune response can have devastating results. For example, pure red cell aplasia can result from neutralizing antibodies to epoetin alpha. 1,2 It is well established that protein aggregates in therapeutic protein products can enhance immunogenicity2, and such an effect is therefore an important risk factor to consider when assessing product quality. The purpose of this commentary is to accomplish the following: i. provide brief summaries on the factors affecting protein aggregation and the key aspects of protein aggregates that are associated with immunogenicity; ii. emphasize the current scientific gaps in understanding and analytical limitations for quantitation of species of large protein aggregates that are referred to as subvisible particles, with specific consideration of those particles 0.1–10 μm in size; iii. offer a rationale for why these gaps may compromise the safety and/or efficacy of a product; iv. provide scientifically sound, risked based recommendations/conclusions for assessment and control of such aggregate species

Genes involved in brassinosteroids's metabolism and signal transduction pathways Genes envolvidos nas vias de biossíntese e de transdução de sinal de brassinoesteróides

Brassinosteroids (BRs) are plant steroids essential for the normal growth and development, which carry an oxygen moiety at C-3 and additional ones at one or more of the C-2, C-6, C-22 and C-23 carbon atoms. In the past few years, application of molecular genetics allowed significant progress on the understanding of the BRs biosynthetic pathway regulation and on the identification of several components of their signal transduction pathway, as well. Search in eletronic databases show dozens of records for brassinosteroid-related genes for the last twelve months, demonstrating the big efforts being carried out in this field. This review highlights the recent advances on the characterization of genes and mutations that are helping to unravel the molecular mechanisms involved in the BRs synthesis/metabolism, perception and response, with especial emphasis on their role in plant cell elongation. Aspects of the involvement of BRs on the regulation of cell cycle-controlling proteins are discussed as well.<br>Brassinoesteróides são esteróides vegetais, essenciais para o crescimento e o desenvolvimento, que apresentam um oxigênio no carbono C-3 e oxigênios adicionais em um ou mais dos átomos de carbono C-2, C-6, C-22 e C-23. Nos últimos anos, a aplicação de técnicas de genética molecular possibilitou progresso significativo no entendimento da regulação da via biossintética e na identificação de vários componentes da via de transdução de sinal de brassinoesteróides. Buscas em bases de dados eletrônicas mostram dúzias de registros para genes relacionados a brassinoesteróides nos últimos doze meses, demonstrando os grandes esforços desenvolvidos neste campo. Esta revisão destaca os recentes avanços na caracterização de genes e mutações que estão auxiliando na elucidação dos mecanismos moleculares envolvidos na síntese/metabolismo, e percepção e resposta de brassinoesteróides, com ênfase especial no seu papel no alongamento de células vegetais. Aspectos do envolvimento de BRs na regulação de proteínas que controlam o ciclo cellular também são discutidos

Applicability and accuracy of pretest probability calculations implemented in the NICE clinical guideline for decision making about imaging in patients with chest pain of recent onset

Cardiolog